Pharmaceuticals News and Research

RSS

China Pharma first-quarter revenue up 16% to $15.1 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

11 May 2010

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010.

11 May 2010

JHP Pharmaceuticals completes successful GMP/Pre Approval Audit by FDA CDER

JHP Pharmaceuticals' sterile manufacturing site based in Rochester, Michigan completed a successful GMP (Good Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug Administration (FDA) drug division (CDER).

11 May 2010

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31, 2010.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.

11 May 2010

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv-, Ph.D., of the University of Toronto.

11 May 2010

Orexigen Therapeutics first-quarter net loss decreases to $14.1 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2010. For the quarter ended March 31, 2010, Orexigen reported a net loss of $14.1 million, or $0.30 per share attributable to common stockholders, as compared to a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, for the first quarter of 2009.

11 May 2010

Jazz Pharmaceuticals announces common stock public offering

Jazz Pharmaceuticals, Inc. announced today that it is offering to sell 7 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.

11 May 2010

ACADIA Pharmaceuticals reports increased revenue in first-quarter 2010

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the first quarter ended March 31, 2010.

11 May 2010

Merck, Glenmark settle ZETIA patent litigation

Merck & Co., Inc. and Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals, Ltd. have reached an agreement to settle their patent litigation involving Glenmark's challenge to Merck's patent covering ZETIA ® (ezetimibe). Specifically, Glenmark challenged Merck's basic compound patent, RE 37,721 (the "721 patent") on numerous grounds.

11 May 2010

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided a business update.

11 May 2010

Jubilant Organosys reports 17.7% increase in fourth-quarter consolidated revenue

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, today announced its financial results for Q4 & FY2010.

10 May 2010

ImmunoGen announces underwriter's exercise of over-allotment option

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 1,350,000 shares of common stock at a public offering price of $8.00 per share.

10 May 2010

Takeda appoints BNY Mellon as depositary bank for sponsored ADR program

BNY Mellon, the global leader in asset management and securities servicing, has been appointed by Takeda Pharmaceutical Company Limited (Takeda) as the depositary bank for its sponsored American depositary receipt (ADR) program. Each Takeda ADR represents one-half of a common share and trades on the over-the-counter (OTC) market under the symbol TKPYY. Takeda's common shares trade on the Tokyo Stock Exchange as well as four other exchanges in Japan under the code "4502." Previously, Takeda traded as an unsponsored ADR program serviced by multiple depositaries.

10 May 2010

CVS calls on FDA to suspend use of contaminated rotavirus vaccines

On Friday, the Food and Drug Administration (FDA) convened a panel of experts to review recent findings that rotavirus vaccines given to infants in the U.S., Rotateq, produced by Merck Pharmaceuticals and Rotarix produced by GlaxoSmithKline, are contaminated with DNA from pig viruses PCV1 and PCV2. On March 22nd the FDA Commissioner asked doctors to suspend use of the Rotarix vaccine due to the contamination. Upon additional testing, Rotateq was also found to be contaminated.

10 May 2010

Eisai enters Canadian pharmaceutical market

Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.

10 May 2010